Compare · ORKA vs VNRX
ORKA vs VNRX
Side-by-side comparison of Oruka Therapeutics Inc. (ORKA) and VolitionRX Limited (VNRX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ORKA and VNRX operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- ORKA is the larger of the two at $4.89B, about 863.1x VNRX ($5.7M).
- Over the past year, ORKA is up 162.1% and VNRX is down 98.0% - ORKA leads by 260.1 points.
- ORKA has been more active in the news (3 items in the past 4 weeks vs 2 for VNRX).
- ORKA has more recent analyst coverage (11 ratings vs 4 for VNRX).
PerformanceORKA+162.07%VNRX-98.03%
2025-10-20+0.00%2026-10-16
- Company
- Oruka Therapeutics Inc.
- VolitionRX Limited
- Price
- $71.99-2.53%
- $0.18-4.52%
- Market cap
- $4.89B
- $5.7M
- 1M return
- -26.35%
- -34.95%
- 1Y return
- +162.07%
- -98.03%
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- AMEX
- IPO
- 2015
- News (4w)
- 3
- 2
- Recent ratings
- 11
- 4
VNRX
VolitionRX Limited
VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. It sells Nu.Q Vet Cancer Screening Test for veterinary applications. The company also develops blood-based Nu.Q immunoassays to detect specific biomarkers. In addition, it is developing various veterinary products, including a treatment monitoring test, a disease recurrence test, and a point-of-care platform. VolitionRx Limited is based in Austin, Texas.
Latest ORKA
- SEC Form 4 filed by Oruka Therapeutics Inc.
- SEC Form 4 filed by Oruka Therapeutics Inc.
- Chief Executive Officer Klein Lawrence Otto exercised 25,000 shares at a strike of $7.80 and sold $2,090,593 worth of shares (25,000 units at $83.62) as part of a pre-agreed trading plan (SEC Form 4)
- Oruka Therapeutics Announces Positive Week 28 Data for ORKA-001 from the Ongoing EVERLAST-A Trial Showing Deepening of Responses Without Additional Dosing
- Senior Vice President, Finance Agarwal Arjun sold $51,035 worth of shares (533 units at $95.75) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 14,219 units (SEC Form 4)
- General Counsel Quinlan Paul T exercised 10,000 shares at a strike of $7.80 and sold $936,417 worth of shares (10,000 units at $93.64) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Medical Officer Goncalves Joana exercised 7,000 shares at a strike of $7.32 and sold $734,145 worth of shares (7,947 units at $92.38) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 31,771 units (SEC Form 4) (for tax liability)
- Senior Vice President, Finance Agarwal Arjun sold $926,010 worth of shares (10,019 units at $92.43) as part of a pre-agreed trading plan and exercised 9,459 shares at a strike of $15.88, decreasing direct ownership by 4% to 14,752 units (SEC Form 4) (for tax liability)
- Chief Executive Officer Klein Lawrence Otto sold $234,681 worth of shares (2,452 units at $95.71), decreasing direct ownership by 0.26% to 923,128 units (SEC Form 4) to cover withholding tax
- General Counsel Quinlan Paul T sold $99,443 worth of shares (1,039 units at $95.71), decreasing direct ownership by 3% to 29,995 units (SEC Form 4) to cover withholding tax
Latest VNRX
- Chief Commercial Officer Forterre Gael covered exercise/tax liability with 284 shares, decreasing direct ownership by 2% to 16,284 units (SEC Form 4) (tax liability)
- Chief Operating Officer Michel Gaetan covered exercise/tax liability with 608 shares, decreasing direct ownership by 5% to 12,232 units (SEC Form 4) to cover withholding tax
- VolitionRX Limited filed SEC Form 8-K: Unregistered Sales of Equity Securities
- VolitionRx Shares Further Details and Video of the DETECSEPS Program Launch in France
- VolitionRx Participates in Launch of DETECSEPS Program in France
- VolitionRX Limited filed SEC Form 8-K: Unregistered Sales of Equity Securities
- VolitionRX Limited filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- VolitionRx Limited Announces Pre-Payment in Full of $7.5 million Senior Secured Convertible Promissory Note Due May 20, 2027
- SEC Form EFFECT filed by VolitionRX Limited
- Volition Presents Early Stage I Solid Cancer Detection at the ESMO MAP Conference